PMID- 23537580
OWN - NLM
STAT- MEDLINE
DCOM- 20130930
LR  - 20220318
IS  - 1872-7913 (Electronic)
IS  - 0924-8579 (Linking)
VI  - 41
IP  - 5
DP  - 2013 May
TI  - Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus 
      infection: a meta-analysis of randomised controlled trials.
PG  - 426-33
LID - S0924-8579(13)00022-8 [pii]
LID - 10.1016/j.ijantimicag.2012.12.012 [doi]
AB  - Linezolid is the first available oxazolidinone, possessing broad-spectrum 
      activity against Gram-positive bacteria and a favourable pharmacokinetic profile. 
      The aim of this study was to compare the efficacy and safety of linezolid with 
      vancomycin, the gold-standard treatment, for meticillin-resistant Staphylococcus 
      aureus (MRSA)-related infections. A meta-analysis of randomised controlled trials 
      (RCTs) identified in PubMed, the Cochrane Library and Embase was performed. Nine 
      RCTs, involving 5249 patients, were included in the meta-analysis. The results 
      indicated that linezolid was associated with superior efficacy compared with 
      vancomycin for MRSA-related infection in terms of clinical treatment success [8 
      RCTs, 2174 patients, odds ratio (OR) = 1.77, 95% confidence interval (CI) 
      1.22-2.56] and microbiological treatment success (9 RCTs, 1555 patients, OR = 
      1.78, 95% CI 1.22-2.58). Although no difference was found regarding the overall 
      incidence of drug-related adverse events (AEs) and serious AEs (SAEs) between the 
      linezolid and vancomycin therapy groups (drug-related AEs, 8 RCTs, 5034 patients, 
      OR = 1.20, 95% CI 0.98-1.48; SAEs, 5 RCTs, 2072 patients, OR = 1.00, 95% CI 
      0.74-1.36), the linezolid therapy group was associated with significantly fewer 
      patients experiencing abnormal renal function (reduced by ca. 60% compared with 
      the vancomycin therapy group; 4 RCTs, 2531 patients, OR = 0.39, 95% CI 
      0.28-0.55), which is a well-recognised limitation of vancomycin. This 
      meta-analysis provides evidence that linezolid possesses significant advantages 
      compared with vancomycin and may be a superior alternative for MRSA-related 
      infection.
CI  - Copyright (c) 2013 Elsevier B.V. and the International Society of Chemotherapy. All 
      rights reserved.
FAU - An, Mao Mao
AU  - An MM
AD  - Department of Ophthalmology of Shanghai Tenth People's Hospital, and Tongji Eye 
      Institute, Tongji University School of Medicine, Shanghai 200092, PR China.
FAU - Shen, Hui
AU  - Shen H
FAU - Zhang, Jun Dong
AU  - Zhang JD
FAU - Xu, Guo Tong
AU  - Xu GT
FAU - Jiang, Yuan Ying
AU  - Jiang YY
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20130326
PL  - Netherlands
TA  - Int J Antimicrob Agents
JT  - International journal of antimicrobial agents
JID - 9111860
RN  - 0 (Acetamides)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Oxazolidinones)
RN  - 6Q205EH1VU (Vancomycin)
RN  - ISQ9I6J12J (Linezolid)
SB  - IM
CIN - Int J Antimicrob Agents. 2013 Oct;42(4):377-8. PMID: 23993064
MH  - Acetamides/adverse effects/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/adverse effects/*therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions/epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Kidney/drug effects/physiology
MH  - Kidney Function Tests
MH  - Linezolid
MH  - Male
MH  - Methicillin-Resistant Staphylococcus aureus/*isolation & purification
MH  - Middle Aged
MH  - Oxazolidinones/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Staphylococcal Infections/*drug therapy/*microbiology
MH  - Treatment Outcome
MH  - Vancomycin/adverse effects/*therapeutic use
MH  - Young Adult
EDAT- 2013/03/30 06:00
MHDA- 2013/10/01 06:00
CRDT- 2013/03/30 06:00
PHST- 2012/11/18 00:00 [received]
PHST- 2012/12/20 00:00 [accepted]
PHST- 2013/03/30 06:00 [entrez]
PHST- 2013/03/30 06:00 [pubmed]
PHST- 2013/10/01 06:00 [medline]
AID - S0924-8579(13)00022-8 [pii]
AID - 10.1016/j.ijantimicag.2012.12.012 [doi]
PST - ppublish
SO  - Int J Antimicrob Agents. 2013 May;41(5):426-33. doi: 
      10.1016/j.ijantimicag.2012.12.012. Epub 2013 Mar 26.